These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 30568471)

  • 1. Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis.
    Seko Y; Nishikawa T; Umemura A; Yamaguchi K; Moriguchi M; Yasui K; Kimura M; Iijima H; Hashimoto T; Sumida Y; Okanoue T; Itoh Y
    Diabetes Metab Syndr Obes; 2018; 11():835-843. PubMed ID: 30568471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 3. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease.
    Puchakayala BK; Verma S; Kanwar P; Hart J; Sanivarapu RR; Mohanty SR
    World J Hepatol; 2015 Nov; 7(25):2610-8. PubMed ID: 26557954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials.
    Seko Y; Sumida Y; Sasaki K; Itoh Y; Iijima H; Hashimoto T; Ishii S; Inagaki N
    J Gastroenterol; 2018 Jan; 53(1):140-151. PubMed ID: 28669071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.
    Harrison SA; Ruane PJ; Freilich B; Neff G; Patil R; Behling C; Hu C; Shringarpure R; de Temple B; Fong E; Tillman EJ; Rolph T; Cheng A; Yale K
    JHEP Rep; 2023 Jan; 5(1):100563. PubMed ID: 36644237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study.
    Tobita H; Sato S; Miyake T; Ishihara S; Kinoshita Y
    Curr Ther Res Clin Exp; 2017; 87():13-19. PubMed ID: 28912902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials.
    Bica IC; Stoica RA; Salmen T; Janež A; Volčanšek Š; Popovic D; Muzurovic E; Rizzo M; Stoian AP
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS.
    Borisov AN; Kutz A; Christ ER; Heim MH; Ebrahimi F
    J Clin Endocrinol Metab; 2023 Oct; 108(11):2940-2949. PubMed ID: 37149821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies.
    Reddy YK; Marella HK; Jiang Y; Ganguli S; Snell P; Podila PSB; Maliakkal B; Satapathy SK
    J Clin Exp Hepatol; 2020; 10(3):245-254. PubMed ID: 32405181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus.
    Lai LL; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    Dig Dis Sci; 2020 Feb; 65(2):623-631. PubMed ID: 30684076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.
    De A; Keisham A; Mishra S; Mehta M; Verma N; Premkumar M; Taneja S; Das A; Singh V; Duseja A
    J Clin Exp Hepatol; 2022; 12(2):440-447. PubMed ID: 35535068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additional Effect of Luseogliflozin on Semaglutide in Nonalcoholic Steatohepatitis Complicated by Type 2 Diabetes Mellitus: An Open-Label, Randomized, Parallel-Group Study.
    Miyake T; Yoshida O; Matsuura B; Furukawa S; Hirooka M; Abe M; Tokumoto Y; Koizumi Y; Watanabe T; Takeshita E; Sunago K; Yukimoto A; Watanabe K; Miyazaki M; Kanzaki S; Nakaguchi H; Koizumu M; Yamamoto Y; Kumagi T; Hiasa Y
    Diabetes Ther; 2022 May; 13(5):1083-1096. PubMed ID: 35312970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology.
    Akuta N; Kawamura Y; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Ikeda K; Kumada H
    Intern Med; 2020 Aug; 59(16):1931-1937. PubMed ID: 32448832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study.
    Wu XX; Zheng KI; Boursier J; Chan WK; Yilmaz Y; Romero-Gómez M; El Kassas M; Targher G; Byrne CD; Huang ZM; Zheng MH
    EClinicalMedicine; 2021 Nov; 41():101145. PubMed ID: 34646997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma.
    Jojima T; Wakamatsu S; Kase M; Iijima T; Maejima Y; Shimomura K; Kogai T; Tomaru T; Usui I; Aso Y
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31652578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial.
    Seino H
    Diabetes Ther; 2021 Mar; 12(3):863-877. PubMed ID: 33594581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study.
    Itani T; Ishihara T
    Obes Sci Pract; 2018 Oct; 4(5):477-482. PubMed ID: 30338118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canagliflozin protects against non-alcoholic steatohepatitis in type-2 diabetic rats through zinc alpha-2 glycoprotein up-regulation.
    Kabil SL; Mahmoud NM
    Eur J Pharmacol; 2018 Jun; 828():135-145. PubMed ID: 29608898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of SGLT2 Inhibitors Versus Pioglitazone in the Treatment of Non-alcoholic Fatty Liver Disease or Non-alcoholic Steatohepatitis: A Systematic Review.
    Kaur S; Sojitra V; Zahra A; Hutchinson J; Folawemi O; Bittla P; Ramphall S
    Cureus; 2023 Sep; 15(9):e45789. PubMed ID: 37745748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes.
    Bajaj HS; Brown RE; Bhullar L; Sohi N; Kalra S; Aronson R
    Diabetes Metab; 2018 Dec; 44(6):493-499. PubMed ID: 30149145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.